NCT05411380 2022-11-04
Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.
Sun Yat-sen University
Phase 2 Unknown
Clinical Trials
11 trialsNCT03024580 2019-08-15
MEGA
Instituto Nacional de Cancer, Brazil
Phase 2 Unknown
NCT04023292 2019-07-17
Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT03910712 2019-04-10
Pyrotinib
Peking Union Medical College Hospital
Phase 2 Unknown
NCT02592746 2019-04-08
A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC
Samsung Medical Center
Phase 2 Unknown
NCT02689921 2018-09-28
NEOADAPT
Midwestern Regional Medical Center
Phase 2 Unknown
NCT02910050 2017-12-22
BETTER
Sun Yat-sen University
Phase 2 Unknown
NCT02646735 2017-01-02
FRIEND
ChineseAMS
Phase 2 Unknown
NCT02025712 2014-01-01
Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer
Organisation for Oncology and Translational Research
Phase 2 Unknown
NCT01431053 2013-03-13
Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer
ChineseAMS
Phase 2 Unknown
NCT00687648 2009-06-17
Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Unknown